First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsPredictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
/in Dendritic Cells, Glioblastoma, International PublicationsOverexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway
/in Glioblastoma, International Publications, Newcastle Disease VirusSurvival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
/in Dendritic Cells, Glioblastoma, International PublicationsAdvances in immunotherapeutic research for glioma therapy
/in Dendritic Cells, Glioblastoma, International PublicationsClinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
/in Glioblastoma, Hyperthermia, International PublicationsCo-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma
/in Dendritic Cells, Exosome, Glioblastoma, International PublicationsCuring glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease VirusMacrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer